logo-loader
viewZelira Therapeutics Ltd

Emerald Clinics gets nod for Zelira's opioid sparing clinical trial

The company is establishing and operating a network of clinics specialising in the creation of fit for purpose evidence.

Zelira Therapeutics Ltd - Emerald Clinics gets nod for Zelira's opioid sparing clinical trial
The trial is testing a medicinal cannabinoid oil formulation

Emerald Clinics Ltd (ASX: EMD) has entered into a clinical trial research agreement to accelerate the completion of the Zelira sponsored trial at St Vincent’s Hospital in Melbourne.

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) has now fully enrolled its Phase 1 Dose Escalation

Trial in patients on long-term opioid treatment.

The trial is called “A study to evaluate the safety, tolerability, and pharmacokinetics of a medicinal cannabinoid oil formulation in chronic non-cancer pain participants on long term opioid treatments.”

No serious adverse events from dosing patients have been reported to date and dosing is expected to be completed by April 2020.

Zelira pleased to expand partnership with Emerald Clinics

Emerald Clinics’ managing director and CEO Dr Michael Winlo said: “We are pleased to be working with Zelira, who are investing in the rigorous, product-specific clinical studies required to bring cannabinoid-based medical products into the mainstream where appropriate.

“Undertaking this trial validates our model of co-creating evidence with our patients while providing high-quality care.

“We are excited to be building upon the collaboration announced in 2019 and look forward to leveraging Real World Evidence (RWE) and traditional clinical trials to support Zelira’s strategy and ultimately improve the health and wellbeing of our patients.”

Zelda’s managing director Dr Richard Hopkins said: “We’re also pleased for the opportunity to expand our partnership with Emerald Clinics by bringing them on as a second site.

“We have been impressed by their ability to complement the efforts of the St Vincent team by rapidly screening and enrolling eligible patients into trial.

Trial could be first of its kind

“To our knowledge, this is the first clinical trial to be designed with a primary end-point assessing the efficacy of a full spectrum plant-derived cannabis formulation containing THC and CBD to reduce opioid dependence in chronic non-cancer patients.

Quick facts: Zelira Therapeutics Ltd

Price: 0.032 AUD

ASX:ZLD
Market: ASX
Market Cap: $30.92 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read